Bharucha David 4

What Happened
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals (MIST), received equity awards on Feb 2, 2026: a grant of 204,000 derivative option units and 136,000 restricted stock units (RSUs), for a total of 340,000 contingent shares. Both awards are reported at $0 (no cash paid). These are grants (not open-market purchases or sales) and therefore represent deferred compensation rather than immediate buying or selling of shares.

Key Details

• Transaction date: February 2, 2026; Form 4 filed Feb 4, 2026 (no late filing indicated).
• Grants reported: 204,000 derivative units (option award) and 136,000 RSUs; reported price $0.00.
• Total contingent shares: 340,000.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1 (options): 1/4 of option shares vest on Feb 2, 2027, then 1/36 of the remaining monthly thereafter, contingent on continued service.
  • F2 (RSUs): each RSU converts to one common share upon vesting.
  • F3 (RSU vesting): RSUs vest 1/4 on each of Feb 2 in 2027, 2028, 2029 and 2030, subject to continued service.

Context

• The 204,000 derivative units are option-like awards (not an exercise); no immediate shares were issued or sold.
• The 136,000 RSUs are a promise to deliver shares in the future if vesting conditions are met.
• Grants are routine compensation for executives and are informational rather than a direct market sentiment signal.